证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-09-23 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 中国银河证券股份有限公司：全铭 | | 人员姓名 | | 易方达基金管理有限公司：王俊杰 | | | | 华润元大基金管理有限公司：张磊 | | | | 北京亚宝投资管理有限公司：郭常平 | | | 深圳尊道投资有限公司：张伟生 | | | | | 广东小禹投资管理有限公司：何结领 | | | | 北京亚宝投资管理有限公司：郭常平 | | | 东莞证券股份有限公司 | : 陈毅 | | | | 上海之上资产管理有限公司：周坤 | | ...

Group 1: Company Overview - The company has 17 essential drug varieties listed in 17 countries, with 6 main products entering the essential drug list [3] - The marketing system focuses on self-operated sales while exploring provincial promotion cooperation and terminal outsourcing [3] Group 2: Hospital Operations - The company operates 4 hospitals, with the oncology hospital and Baiyun Hospital's bed capacity currently insufficient to meet demand [4] - The oncology hospital is the only tertiary A oncology specialty hospital in Guizhou Province, with ongoing expansion to increase bed capacity and revenue [4] Group 3: Mergers and Acquisitions - The acquisition of Zhongtai Biochemical Co., Ltd. will enhance the company's international R&D and sales capabilities, focusing on overseas market expansion [4][5] - The company aims to optimize resources globally to improve competitiveness and maximize shareholder returns [5] Group 4: Internet Medical Development - The company is actively developing an internet medical network, with the "Guiyi Cloud" platform already in use, enhancing patient experience and service efficiency [5] - The application of mobile internet in healthcare is expected to lower costs and improve service quality [5] Group 5: Employee Stock Ownership Plan - The basic plan for the employee stock ownership scheme has been agreed upon, with ongoing efforts to finalize the plan for board and shareholder approval [5][6] Group 6: Future Strategic Planning - The company has expanded its business scope to include pharmaceutical distribution and medical services, establishing a comprehensive industry chain [6] - Future strategies include increasing investment in internet healthcare, expanding medical service capacity, and optimizing product structure to enhance market competitiveness [6]

Sales Performance - Sales of Yixinshu and Maixuekang exceeded 100 million yuan from January to September 2015, showing stable growth compared to the same period last year [3] - These two products are currently the top sales items in the company's pharmaceutical sector [3] Medical Services - Hospital operations are normal with steady income growth; bed occupancy rates exceed 100% at the Tumor Hospital and Baiyun Hospital [3] - In May 2015, 300 new beds were added at the Tumor Hospital, and 220 beds were opened at the Renhuai Xinchao Hospital in June [3] - The company is focusing on talent development and optimizing its workforce to ensure sustainable growth in medical services [3][4] Profitability - The current net profit margin for medical services is below 6%, with plans to improve profitability through better management and increased bed capacity [4] - The medical business revenue accounted for 68% of the main business income from January to September 2015 [4] Business Development - The company’s subsidiary, Tongde Pharmaceutical, completed its production line and received GMP certification at the beginning of the year [5] - The major asset restructuring with Zhongtai Biochemical is under review by the regulatory authority, with updates to be disclosed in due course [5][6] Strategic Planning - The company aims to enhance its product structure and optimize its drug distribution network through both organic growth and acquisitions [6] - The "Guiyi Cloud" project is underway, focusing on internet medical services, with initial success in establishing a customer base and service functionalities [6]

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-08-29 | --- | --- | --- | |----------------|--------------------------------------|----------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 海通证券股份有限公司：师成平、廖庆阳 | | | 人员姓名 | 中海基金管理有限公司 | : 郑辰 | | | | | | | 摩根士丹利华基金管理有限公司 | : 缪东航 | | | 上投摩根基金管理有限公司:罗会礼 | | | | 申万菱信基金管理有限公司：杨扬 | | | 时间 | 2015 年 8 月 29 | 日 10:00-11:30 | | 地点 | 公司总部五楼会议室 | | | 上市公司接待人 | 副总经理、董事会秘书 陈 船 | ...

Group 1: Company Overview - The company is Guizhou Xinpang Pharmaceutical Co., Ltd., with the stock code 002390 [1] - The company operates in three main sectors: pharmaceutical manufacturing, pharmaceutical distribution, and medical services [3] Group 2: Medical Services - The company owns 8 hospitals, including the only Grade A tumor specialty hospital in Guizhou, with a total of nearly 4,000 beds [2] - The company has established a stable management and high-end talent team for medical services, providing a solid foundation for development [2] - Future plans include expanding medical services to counties, aiming to establish 20,000 beds in the province within 5 to 10 years [4] Group 3: Pharmaceutical Distribution - In 2015, the pharmaceutical distribution revenue reached 2.48 billion yuan, covering various regions in the province [3] - The company aims to strengthen its marketing capabilities and explore diverse supply chain management models to become a regional leader in pharmaceutical distribution [3] Group 4: Financial Management - The company faces cash flow pressures in pharmaceutical distribution and plans to utilize equity financing, bank loans, and other debt financing methods to manage operational capital [3] - The company is focused on improving management efficiency and profitability in its medical services sector [4] Group 5: Peptide Business - The peptide business accounts for approximately 40% of revenue, while in vitro diagnostic reagents account for about 60% [4] - The company provides customized peptide synthesis and production services for domestic and international pharmaceutical enterprises and research institutions [4]

Company Overview - Xinpang Pharmaceutical was established in 1995 and became a joint-stock company in 2000, listed on the Shenzhen Stock Exchange in 2010. In 2014, the company completed a significant asset restructuring with Keke Pharmaceutical. It has evolved into a comprehensive pharmaceutical group integrating medical services, pharmaceutical distribution, and pharmaceutical manufacturing [2][3]. Financial Performance - The company reported a revenue of 6.655 billion CNY and a net profit attributable to the parent company of 236 million CNY. It operates over 50 subsidiaries and employs nearly 7,000 people [3]. Private Placement Details - The private placement involved issuing 360 million shares at a price of 4.20 CNY per share, which is 80% of the average stock price over the previous 20 trading days. The total amount raised is 1.512 billion CNY, which will be used to repay bank loans and supplement working capital [3]. - Post-issuance, the total share capital will increase from 1.667 billion shares to 2.027 billion shares. Guizhou Jinyu Industrial Investment Partnership will hold 17.76% of the shares, making it the controlling shareholder, while the chairman and his associates will collectively hold 25.05% [3]. Purpose and Significance of the Private Placement - The full subscription by Guizhou Jinyu highlights the chairman's confidence in the company's future development, which is significant for aligning operational and ownership rights. This change in controlling shareholder is expected to streamline governance and clarify the ownership structure, mitigating potential adverse effects from high share pledges and freezes by the current controlling shareholder [3][4]. Development in Medical Services - The company is constructing the Guizhou Medical University Baiyun Clinical Teaching Center, aiming to replicate successful management models within Guizhou and expand into the Southwest region. The tumor hospital is the only tertiary specialized cancer hospital in Guizhou, integrating medical, teaching, research, prevention, health care, rehabilitation, and palliative care [6]. - Baiyun Hospital, a non-profit tertiary hospital, is involved in various national health initiatives and aims to enhance medical education and quality through collaboration with Guizhou Medical University [6]. Pharmaceutical Distribution Network - The company has established a robust pharmaceutical distribution network covering multiple hospitals and pharmaceutical companies in the province, leading to increased scale and profitability. It has also developed a retail pharmacy network supported by its hospitals, enhancing its bargaining power and service quality [7]. - The company plans to integrate resources across its pharmaceutical subsidiaries, improve operational quality, and maintain its position as a leading pharmaceutical enterprise in the province [7].

Group 1: Investor Relations Activity - The investor relations activity included a visit to the tumor hospital and presentations by company executives [2][3] - The event was attended by 15 investors registered through Huachuang Securities and representatives from various regulatory bodies [2] - The meeting took place on December 6, 2018, from 9:30 AM to 12:00 PM at the company's administrative office [2] Group 2: Financial Performance and Challenges - The company's cash flow from operating activities was negative in the first half of 2018, primarily due to increased prepayments for pharmaceuticals following the implementation of the "two-invoice system" [3] - Revenue from the pharmaceutical distribution business increased by 21.05% compared to the previous year [3] Group 3: Business Strategy and Future Plans - The company maintains its strategic direction and management team despite changes in the controlling shareholder [3][4] - The three main business segments are pharmaceutical distribution, medical services, and pharmaceutical manufacturing, with distribution being the largest [4] - Future investments will focus on enhancing medical services to meet market demand and achieve synergy among the three business segments [4] Group 4: Clinical Trials and Market Presence - The tumor hospital has obtained qualifications for drug clinical trials, which aligns with the company's goal of becoming a "high-tech medical service group" [4] - The company has developed over 30 drug abuse testing kits, including fentanyl testing kits, which have been well-received in the European and American markets [5] Group 5: Investor Communication and Market Stability - The company utilizes various channels for investor communication, including on-site research, interactive platforms, and social media [5] - In the first half of 2018, the company implemented share buybacks and encouraged employees to increase their holdings to stabilize the market [5]

证券简称：信邦制药 证券代码：002390 证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2021-5-18 | --- | --- | --- | |----------------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 \n | ■特定对象调研 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n■现场参观 \n□其他 （说明具体形式） | □分析师会议 | | 参与单位名称及 人员姓名 | | 兴全基金、人保养老、中加基金、长城基金、开源证券、 泓澄投资、中信资本、中信证券、东方证券、兴业证券 | | 时间/地点 | ...

编号：2021-11-3 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （说明具体形式） 证券简称：信邦制药 证券代码：002390 证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 东吴证券、天风证券、高毅资产、嘉实基金、安信基 | --- | --- | |-------------------------|------------------------------------------------------------| | | | | | | | 参与单位名称及 人员姓名 | 金、南土资产、国信永丰基金、长城基金、广银理财、济 民可信 | | 时间/地点 | 时间： 2021 年 11 月 3 日 9:30 至 11:30 | | | 地点：贵阳市乌当区新添大道北段 83 号科开 1 号苑 | | | 董事长：安怀略 | | | 总经理：孔令忠 | | 上市公司接待 | 董事会秘书：陈船 | | 人员姓名 | 董事长助理：安吉 | | | 医院及流通公司管理人员 | | | 一 ...